Archived explainer. For the current picture see today's JNJ page.
Why Is JOHNSON & JOHNSON (JNJ) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 31, 2026 at 1:13 AM ET · reviewed against 8 wire stories
JOHNSON & JOHNSON (JNJ) is drawing unusual attention today. Our newswire has captured 8 stories on JNJ across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 59/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Johnson & Johnson stock is moving lower today, down 2.0% to $268.04 after eight sessions, amid recent insider selling and a broader reevaluation of its fundamentals. The stock has been outperforming the consumer staples sector over the past year but faces scrutiny as executives and top insiders have sold a combined $61.0 million in shares since late July. Recent news of new FDA approvals for JNJ therapies has not yet offset the selling pressure.
What Happened
The stock’s decline follows a series of insider transactions, with key executives including CEO Joaquin Duato and EVP Jennifer Taubert selling shares in recent weeks. These sales, totaling $61.0 million in the last 90 days, have raised questions about internal confidence. Meanwhile, JNJ has secured regulatory approvals for treatments in rare anemias and pediatric ulcerative colitis, which could support long-term growth but have not yet driven near-term momentum. The stock’s recent performance has also been weighed down by its relatively high P/E of 31.1 and a beta of 0.23, suggesting it may underperform in a more volatile market environment.
What The Data Shows
Over the past eight trading sessions, JNJ has fallen 2.0% from $273.41 to $268.04, a move that aligns with the broader insider selling trend. The stock currently trades within its 52-week range of $173.33 to $276.47. Insiders have executed six sell transactions in the last 90 days with no buy activity. Congressional trades show a mixed picture, with 16 buys and 10 sells in the same period. Social media chatter has remained minimal, with only three posts in the last seven days and none in the last 24 hours.
What To Watch
Investors should monitor the stock ahead of any upcoming earnings report or additional insider activity. With JNJ’s fundamentals showing mixed signals and recent insider moves drawing attention, further clarity on management’s strategic direction and market conditions will be key.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
JNJ · Aug 31 session (5-min) · -0.69% vs prior close · updated 8:56 PM ETAI sentiment, last 36h · averaged over 8 stories · 59/100 bullish
The headlines behind the move
Story flow · 3 stories on the wire, last 36h · hover or tap a dot for the headline
13d agoYahoo TopNEUTRAL 50General
How a 79-Year-Old Widow Built a $6,100 Monthly Paycheck Around O, JNJ, and PFF
Converting a nest egg into a reliable monthly paycheck sounds straightforward until you realize the yield tier you choose can demand nearly three times as much capital for the same income target. A 79-year-old widow with fixed expenses and no room for error found a middle path most retirees overlook entirely.
14d agoYahoo TopNEUTRAL 54Analyst
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
14d agoThe Motley FoolNEUTRAL 54Analyst
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
14d agoYahoo FinanceBULLISH 57Analyst
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?
Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.
14d agoBarchartBULLISH 57Analyst
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?
Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.
15d agoYahoo FinanceBULLISH 67M&A
Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
CAR-T therapies are transforming treatment for certain cancers and raising hopes for patients. Several approved therapies have delivered strong responses for patients with advanced blood cancers where conventional treatments have failed. It’s no wonder the CAR-T market is expanding rapidly. The global CAR-T therapy market is projected to grow from $2.69 billion in 2022 to […]
15d agoYahoo FinanceBULLISH 64Analyst
Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.
JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.
15d agoYahoo TopBULLISH 67Product/PR
Did A Product Swap Fuel JNJ Stock’s 54% Surge?
The signs were not in the headline growth rate but in which two products were trading places.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →